Pandion Therapeutics is a clinical-stage, privately-held biotechnology company developing modular protein therapeutics for autoimmune disease.
Pandion develops bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment of patients with autoimmune and inflammatory disease and organ transplants.
Pandion Therapeutics was founded in 2016 by Anthony Coyle, Jo Viney, Alan Crane, and David Sachs. The company is headquartered in Cambridge, Massachusetts.
Pandion Therapeutics is developing its lead drug candidate, PT101, an IL-2 mutein Fc fusion protein that preferentially expands regulatory T cells, as well as a robust pipeline of systemic immune modulators and tissue-targeted therapeutics focused on the gut, liver, skin, kidneys, and pancreas.
Pandion’s approach has the potential to more effectively induce and sustain response and remission in patients with many autoimmune and inflammatory conditions.Pandion’s approach has the potential to more effectively induce and sustain response and remission in patients with many autoimmune and inflammatory conditions.
Pandion is backed by Access Biotechnology, Boxer Capital, Polaris Partners, Versant Ventures, RA Capital, OrbiMed and others. The company raised $80M in a Series B round on Apr 01, 2020. This brings Pandion's total funding to $138M to date.